Clinical Trials

S1007: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (H-28669)

S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Women with hormone-responsive breast cancer with 1-3 positive lymph nodes involved and have already had the cancer removed by surgery are being sought to participate in a Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

This study will use a commercially available test called Oncotype DX® that looks at multiple genes related to breast cancer. The combination of the test results produces a score that is useful in guiding treatment choices for patients with node-negative breast cancer. (The higher the score, the more likely that the patient¹s breast cancer will come back after surgery.) If your score is 25 or less, you may be interested in participating in the larger study to see if patients should receive chemotherapy as well as hormone therapy or not based on the score. Many women receive both but no one really knows some women are receiving chemotherapy who do not need it. We would like to see if this test is also helpful for making treatment choices for patients that are node positive.

If you are interested, please call Dorothy at (713) 798-9143 or Afife at (713) 798-1911.

For study details see Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer.